SCHEMBL6490763

SCHEMBL6490763

Cc1cc2cc(NC(=O)C3CCCC3)ccc2n1C(=O)c1ccccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.53
NPSR1 Q6W5P4 1/20 0.47
NR2E3 Q9Y5X4 2/20 0.47
NPY2R P49146 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HPGD P15428 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
F2R P25116 1/20 0.44
USP2 O75604 1/20 0.44
EPHX2 P34913 1/20 0.43
UBE2M P61081 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
PTBP1 P26599 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480891 0.89 NPSR1 (0.50) GRM4NPSR1NPY2RMAOAMAOB
SCHEMBL6481059 0.88 NPSR1 (0.49) GRM4NPSR1NPY2RMAOAMAOB
SCHEMBL6492262 0.87 NPSR1 (0.47) GRM4NPSR1NPY2RMAOAMAOB
SCHEMBL6493898 0.87 GRM4 (0.52) GRM4NPSR1MAOAMAOBALDH1A1
SCHEMBL6492402 0.85 NPSR1 (0.46) GRM4NPSR1NPY2RMAOAMAOB
SCHEMBL6487994 0.85 MEN1 (0.46) NPSR1HPGDUBE2MDCUN1D1LMNA
SCHEMBL6492666 0.84 NPSR1 (0.45) GRM4NPSR1NPY2RMAOAMAOB
SCHEMBL6480181 0.84 NPSR1 (0.51) NPSR1MAOAMAOBHPGDALDH1A1
SCHEMBL6480935 0.83 NPSR1 (0.50) NPSR1MAOAMAOBHPGDALDH1A1
SCHEMBL6489974 0.83 JAK2 (0.43) NPSR1MAOAMAOBGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 GRM4 3740/4885NPSR1 556/4885NR2E3 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.